For the year ending 2025-12-31, CGEM has $448,374K in assets. $39,644K in debts. $88,332K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 88,332 | |||
| Short-term investments | 289,564 | |||
| Prepaid expenses and other current assets | 8,860 | |||
| Total current assets | 386,756 | |||
| Total property and equipment, gross | 1,390 | |||
| Less accumulated depreciation | 969 | |||
| Property and equipment, net | 421 | |||
| Operating lease right-of-use assets | 2,630 | |||
| Other assets | 297 | |||
| Long-term investments | 58,270 | |||
| Total assets | 448,374 | |||
| Accounts payable | 841 | |||
| Accrued expenses and other current liabilities | 36,120 | |||
| Operating lease liabilities, current | 780 | |||
| Total current liabilities | 37,741 | |||
| Operating lease liabilities, net of current portion | 1,903 | |||
| Total liabilities | 39,644 | |||
| Common stock, 0.0001 par value, 150,000,000 shares authorized as of december 31, 2025 and 2024 60,244,136 and 58,510,610 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 6 | |||
| Additional paid-in capital | 995,823 | |||
| Accumulated other comprehensive gain (loss) | 1,020 | |||
| Accumulated deficit | -588,119 | |||
| Total cullinan stockholders' equity | 408,730 | |||
| Noncontrolling interests | 0 | |||
| Total stockholders' equity | 408,730 | |||
| Total liabilities and stockholders' equity | 448,374 | |||
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)